specialty-pharmaceuticals
(2)
James O'Mara
James (Jim) O'Mara is the President and CEO of Neurogastrx, a Woburn, Massachusetts specialty pharmaceutical company developing oral therapies for gastrointestinal disorders. A pharmacist by training with decades in biotech, he was one of the original members of the LINZESS team at Ironwood Pharmaceuticals, where he rose to Senior Vice President of Corporate Development and drove licensing deals across the U.S., Europe, Japan and China. At Neurogastrx he raised a $60 million Series B and is steering the company's lead candidate, NG101, through clinical studies aimed at the nausea and vomiting that lead many patients to abandon GLP-1 weight-loss and diabetes medicines.
Heidi Gillmore
Heidi Gillmore is a commercial leadership executive at TerSera Therapeutics, the Deerfield, Illinois specialty pharmaceutical company she helped build from its 2016 inception. Across roles spanning marketing, strategy, business development and running TerSera's US oncology business, she has helped turn a portfolio of 'one-and-only' therapeutics, including the prostate and breast cancer drug Zoladex, into a durable commercial enterprise. A University of Northern Iowa graduate with a University of Chicago credential, she sits on the board of the Illinois Biotechnology Innovation Organization and has spent her career taking specialty and orphan medicines from acquisition to market.